title: Cost analysis of glaucoma medications.
abstract: OBJECTIVE
  To provide patients and health care providers with calculated yearly costs of topical glaucoma medications.
  
  
  METHODS
  Prospective, experimental, laboratory study.
  
  
  METHODS
  Using the average wholesale price and common dosing patterns, we calculated the theoretical yearly cost of glaucoma medications.
  
  
  RESULTS
  Calculated yearly cost ranged from $150.81 for generic timolol maleate 0.5% (Falcon Pharmaceuticals, Ltd, Fort Worth, Texas, USA) to $697.42 for Cosopt (Merck & Co, West Point, Pennsylvania, USA), and as high as $873.98 for a three-times-daily dose of Alphagan P 0.15% (Allergan, Inc, Irvine, California, USA). Among brand name beta-blockers, yearly cost ranged between $203.47 for Timoptic 0.5% (Merck & Co) and $657.24 for Betoptic S (Alcon Laboratories, Fort Worth, Texas, USA). Generic beta-blockers consistently were more economical than their brand-name counterparts. Yearly cost of prostaglandin analogs ranged from $427.69 for Travatan (Alcon) to $577.62 for Lumigan (Allergan). The two carbonic anhydrase inhibitors Azopt (Alcon) and Trusopt (Merck & Co), yielded similar economic profiles. Alphagan P 0.15% had yearly calculated costs of $559.08 for twice daily dosing per eye. The generic selective alpha(2)-agonist brimonidine tartrate 0.2% (Bausch & Lomb Pharmaceuticals, Tampa, Florida, USA) costs approximately $352.89 and $529.34 per year for the respective two and three drops daily per eye regimens.
  
  
  CONCLUSIONS
  Nonselective beta-blockers remain the most inexpensive class of glaucoma medications. Bottle size may impact yearly glaucoma medication expenditures. Costs of glaucoma medications may impact decision making in the medical management of glaucoma.
authors.affiliation: Department of Ophthalmology, Scott and White Memorial Hospital and Clinic, The Texas A&M University System Health Science Center College of Medicine, Temple, Texas, USA.
authors.forename: Nathan R
authors.initials: NR
authors.lastname: Rylander
authors.forename: Steven D
authors.initials: SD
authors.lastname: Vold
mesh_terms: D000959:Antihypertensive Agents / Q000191:economics*; D003365:Costs and Cost Analysis; D016527:Drug Costs; D011307:Drug Prescriptions / Q000191:economics; D016568:Drugs, Generic / Q000191:economics; D005901:Glaucoma / Q000191:economics*; D006801:Humans; D008962:Models, Theoretical; D009883:Ophthalmic Solutions / Q000191:economics*; D011446:Prospective Studies
chemical_list: D000959:Antihypertensive Agents; D016568:Drugs, Generic; D009883:Ophthalmic Solutions